Menu

Research

Sydney Retina Clinic and Day Surgery is proud to be associated with a research department named the Sydney Institute of Vision Science. All members of the research team have a strong background in both clinical and laboratory research and are dedicated to the development of new treatment for retinal disease.

In recent months we have been involved in a number of projects, some of which are already completed, and some which are on-going.

 

SPONSORED TRIALS

HAWK (ALCON RTH258-C001)
A Two Year, Randomized, Double-Masked, Multi-Center, Three-Arm Study Comparing the Efficacy and Safety of RTH255 versus Aflibercept in Subjects with Exudative Age-Related Macular Degeneration

AUSSIEDEX (BAYER CMO-AP-EYE-0438)
Phase 4, open-label, non-randomized, prospective study of OZURDEX® in the Treatment of Diabetic Macular Oedema

SEQUOIA (ALLERGAN 150998-006)
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration

FILLY (APEILLIS POT-CP121614)
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA)

FLUID (NOVARTIS CRFB002AAU15)
A Phase IV, randomised, controlled study investigating the efficacy and safety of ranibizumab “inject and extend” using an intensive retinal fluid retreatment regimen compared to a relaxed retinal fluid retreatment regimen in patients with wet age-related macular degeneration (Wet AMD)
.

RIVAL (NOVARTIS CRFB002AAU17)
Development of new geographic atrophy in patients with neovascular (wet) age-related macular degeneration: a comparison of ranibizumab and aflibercept

 

UPCOMING TRIAL

CENTERA (BAYER BAY86-5321/17514)
A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion

 

INVESTIGATOR INITIATED STUDIES

SAFFRON
Neuroprotection for the macula.

DONOR EYE
Clinicopathological Correlation in Macular Degeneration.

EYLEA DME
Intravitreal Aflibercept for the treatment of treatment resistant diabetic macular oedema.